Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stavroula Baritaki

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Critical Reviews in Oncogenesis|February 9, 2026
Research Article: The Dysregulated YY1-Bcl-2-c-Myc Axis in Non-Hodgkin Lymphoma: Validation by Bioinformatic AnalysesMai P Ho, Evagelia Skouradaki, Etini Otumo, et al.
Cells|December 24, 2021
Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and ImmunotherapyGiasemi C Eptaminitaki, Nora Wolff, Dimitris Stellas, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2009
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinomaApostolos Zaravinos, Peggy Kanellou, Stavroula Baritaki, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|November 5, 2025
Opposing roles of YY1 and RKIP in cancer progression and therapy resistanceChristos Rigopoulos, Stavroula Baritaki, Ilias Georgakopoulos-Soares, et al.
Toxicology Letters|December 7, 2007
Activation-induced cell death signalling in CD4+ T cells by staphylococcal enterotoxin AFilippos Porichis, Antigoni Morou, Stavroula Baritaki, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|July 22, 2025
Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphomaMai P Ho, Evagelia Skouradaki, Stavroula Baritaki, et al.
Molecular Cancer Therapeutics|April 14, 2007
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1Stavroula Baritaki, Sara Huerta-Yepez, Toshiyuki Sakai, et al.
International Journal of Molecular Sciences|August 14, 2025
Pan-Cancer Computational Analysis of RKIP (<i>PEBP1</i>) and LKB1 (<i>STK11</i>) Co-Expression Highlights Distinct Immunometabolic Dynamics and Therapeutic Responses Within the Tumor MicroenvironmentEvangelia Skouradaki, Apostolos Zaravinos, Maria Panagopoulou, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 2, 2017
Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancerStephanie Wottrich, Samantha Kaufhold, Emmanuel Chrysos, et al.
Pathology Oncology Research : POR|July 2, 2008
K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinomaIoannis D Lyronis, Stavroula Baritaki, Ioannis Bizakis, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Critical Reviews in Oncogenesis|February 9, 2026
Research Article: The Dysregulated YY1-Bcl-2-c-Myc Axis in Non-Hodgkin Lymphoma: Validation by Bioinformatic AnalysesMai P Ho, Evagelia Skouradaki, Etini Otumo, et al.
Cells|December 24, 2021
Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and ImmunotherapyGiasemi C Eptaminitaki, Nora Wolff, Dimitris Stellas, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2009
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinomaApostolos Zaravinos, Peggy Kanellou, Stavroula Baritaki, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|November 5, 2025
Opposing roles of YY1 and RKIP in cancer progression and therapy resistanceChristos Rigopoulos, Stavroula Baritaki, Ilias Georgakopoulos-Soares, et al.
Toxicology Letters|December 7, 2007
Activation-induced cell death signalling in CD4+ T cells by staphylococcal enterotoxin AFilippos Porichis, Antigoni Morou, Stavroula Baritaki, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|July 22, 2025
Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphomaMai P Ho, Evagelia Skouradaki, Stavroula Baritaki, et al.
Molecular Cancer Therapeutics|April 14, 2007
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1Stavroula Baritaki, Sara Huerta-Yepez, Toshiyuki Sakai, et al.
International Journal of Molecular Sciences|August 14, 2025
Pan-Cancer Computational Analysis of RKIP (<i>PEBP1</i>) and LKB1 (<i>STK11</i>) Co-Expression Highlights Distinct Immunometabolic Dynamics and Therapeutic Responses Within the Tumor MicroenvironmentEvangelia Skouradaki, Apostolos Zaravinos, Maria Panagopoulou, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 2, 2017
Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancerStephanie Wottrich, Samantha Kaufhold, Emmanuel Chrysos, et al.
Pathology Oncology Research : POR|July 2, 2008
K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinomaIoannis D Lyronis, Stavroula Baritaki, Ioannis Bizakis, et al.
Pageof 8